source
- Lilly-backed TRex Bio raises $117M in IPO as hypertension biotech Retension secures $45M listingTRex Bio, a biotech backed by Eli Lilly, completed its initial public offering, generating $116.7 million in gross proceeds. The company sold 8.3 million shares at $14 each, landing at the lower en…
- FDA review flags limited efficacy of Revolution's pancreatic cancer drug Rasonque, shares drop 6%Shares of Revolution Medicines fell about 6% after the Food and Drug Administration released review documents that suggest its pancreatic cancer therapy Rasonque may not work as well in all patient…